Advertisement
DGX vs MDT
Which Stock Would AI Choose? Quest Diagnostics (DGX) vs. Medtronic (MDT) Stock Comparison
Key Takeaways
- DGX has delivered a year-to-date (YTD) gain of 14.14%, outpacing MDT's 10.79% rise amid recent healthcare sector volatility.
- DGX recently beat Q1 earnings expectations with EPS (earnings per share) of $2.50 versus $2.37 estimated, alongside raised full-year revenue guidance to $11.84 billion.
- MDT completed the $585 million acquisition of CathWorks, bolstering its cardiovascular offerings, though shares have faced downward pressure from analyst price target reductions.
- Both stocks trade at comparable price-to-earnings (PE) ratios around 22-24, reflecting balanced valuations in the healthcare space.
- MDT's larger market capitalization of $109 billion dwarfs DGX's $21.7 billion, offering scale advantages but higher exposure to global risks.
- Recent momentum favors DGX with pre-market gains following earnings, contrasting MDT's intraday declines.
Introduction
Quest Diagnostics (DGX) and Medtronic (MDT) represent distinct pillars of the healthcare sector: laboratory diagnostics versus medical devices. This comparison analyzes their recent market positioning, performance trends, and key drivers, aiding investors seeking diversified exposure or relative value plays. Traders focused on healthcare momentum, stability amid economic shifts, or sector rotation may find insights into how these stocks stack up in the current environment, where diagnostic demand and device innovation intersect with broader market sentiment.
DGX Overview and Recent Performance
Quest Diagnostics (DGX) is a leading provider of diagnostic information services, including laboratory testing for health systems, physicians, and patients. In recent market activity, DGX shares have shown resilience, closing around $196 with strong pre-market gains following a Q1 earnings beat. Revenue reached $2.90 billion, exceeding estimates, while EPS hit $2.50 against expectations of $2.37, prompting raised full-year guidance. YTD performance stands at 14.14%, supported by steady demand for routine and advanced testing. Sentiment has improved on operational efficiency and volume growth, though shares remain below the 52-week high of $213.50 amid broader sector fluctuations.
MDT Overview and Recent Performance
Medtronic (MDT) plc is a global medtech giant specializing in devices for cardiovascular, diabetes, and neuromodulation therapies. Recent weeks have seen mixed results, with shares closing near $85 after a 1.38% daily decline. The Q3 fiscal 2026 results showed adjusted EPS of $1.36 and revenue of $9.02 billion, alongside strategic moves like the $585 million CathWorks acquisition to enhance imaging capabilities. YTD gains of 10.79% lag peers, pressured by analyst price target cuts and stable Q1 outlooks. Trading above the 52-week low of $79.93 but down from $106.33 high, sentiment reflects acquisition integration and regulatory hurdles.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases 25 top-performing AI trading bots curated from over 351 available models that trade thousands of tickers across stocks, ETFs, and crypto. These bots employ diverse strategies like swing trading, trend following, and volatility corridors, with timeframes from 5 minutes to 60 minutes. Standout stats include annualized returns up to 167.82%, win rates ranging 53.91% to 87.72%, profit factors as high as 11.70, and profit-to-drawdown ratios exceeding 22 in some cases. Focused on high-momentum sectors such as semiconductors and aerospace, they offer copy-trading options tailored to current conditions. Explore these bots to align automated strategies with your portfolio goals.
Head-to-Head Comparison
DGX’s service-based model benefits from recurring diagnostic volumes less sensitive to capital spending cycles, contrasting MDT’s product-driven approach reliant on device sales and procedural adoption. Growth drivers diverge: DGX leverages base business expansion and efficiency, while MDT pursues M&A (mergers and acquisitions) and innovation in areas like TAVR (transcatheter aortic valve replacement). Recent momentum tilts to DGX with earnings-driven upside, versus MDT’s post-earnings dips. Risk factors include reimbursement pressures for both, but MDT faces greater international exposure. Market sentiment favors DGX’s stability over MDT’s scale trade-offs.
Tickeron AI Verdict
Tickeron’s AI models currently lean toward DGX due to superior recent trend consistency, positive earnings catalyst, and relative stability in diagnostics demand. MDT offers long-term potential from its portfolio breadth and acquisitions, but short-term positioning appears less favorable amid downward momentum. This probabilistic edge reflects observable data patterns rather than guarantees.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DGX is a Buy and MDT is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DGX’s FA Score shows that 2 FA rating(s) are green whileMDT’s FA Score has 1 green FA rating(s).
- DGX’s FA Score: 2 green, 3 red.
- MDT’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DGX’s TA Score shows that 4 TA indicator(s) are bullish while MDT’s TA Score has 5 bullish TA indicator(s).
- DGX’s TA Score: 4 bullish, 5 bearish.
- MDT’s TA Score: 5 bullish, 5 bearish.
Price Growth
DGX (@Medical Specialties) experienced а -4.25% price change this week, while MDT (@Medical/Nursing Services) price change was -1.38% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.70%. For the same industry, the average monthly price growth was +2.77%, and the average quarterly price growth was -3.13%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +0.45%. For the same industry, the average monthly price growth was -3.28%, and the average quarterly price growth was -15.87%.
Reported Earning Dates
DGX is expected to report earnings on Jul 23, 2026.
MDT is expected to report earnings on Aug 25, 2026.
Industries' Descriptions
@Medical Specialties (+0.70% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Medical/Nursing Services (+0.45% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| DGX | MDT | DGX / MDT | |
| Capitalization | 21.4B | 101B | 21% |
| EBITDA | 2.22B | 9.36B | 24% |
| Gain YTD | 12.553 | -16.805 | -75% |
| P/E Ratio | 21.39 | 21.25 | 101% |
| Revenue | 11.3B | 35.5B | 32% |
| Total Cash | 393M | 8.38B | 5% |
| Total Debt | 6.41B | 28.1B | 23% |
DGX | MDT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 67 | 12 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 4 Undervalued | 3 Undervalued | |
PROFIT vs RISK RATING 1..100 | 29 | 100 | |
SMR RATING 1..100 | 60 | 74 | |
PRICE GROWTH RATING 1..100 | 35 | 61 | |
P/E GROWTH RATING 1..100 | 57 | 62 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MDT's Valuation (3) in the Medical Specialties industry is in the same range as DGX (4) in the Servicestothe Health Industry industry. This means that MDT’s stock grew similarly to DGX’s over the last 12 months.
DGX's Profit vs Risk Rating (29) in the Servicestothe Health Industry industry is significantly better than the same rating for MDT (100) in the Medical Specialties industry. This means that DGX’s stock grew significantly faster than MDT’s over the last 12 months.
DGX's SMR Rating (60) in the Servicestothe Health Industry industry is in the same range as MDT (74) in the Medical Specialties industry. This means that DGX’s stock grew similarly to MDT’s over the last 12 months.
DGX's Price Growth Rating (35) in the Servicestothe Health Industry industry is in the same range as MDT (61) in the Medical Specialties industry. This means that DGX’s stock grew similarly to MDT’s over the last 12 months.
DGX's P/E Growth Rating (57) in the Servicestothe Health Industry industry is in the same range as MDT (62) in the Medical Specialties industry. This means that DGX’s stock grew similarly to MDT’s over the last 12 months.
| DGX | MDT | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 63% |
| Stochastic ODDS (%) | 2 days ago 62% | 2 days ago 52% |
| Momentum ODDS (%) | 2 days ago 45% | 2 days ago 56% |
| MACD ODDS (%) | 2 days ago 53% | 2 days ago 49% |
| TrendWeek ODDS (%) | 2 days ago 43% | 2 days ago 56% |
| TrendMonth ODDS (%) | 2 days ago 57% | 2 days ago 45% |
| Advances ODDS (%) | 19 days ago 63% | 8 days ago 51% |
| Declines ODDS (%) | 2 days ago 45% | 16 days ago 58% |
| BollingerBands ODDS (%) | 2 days ago 48% | 2 days ago 63% |
| Aroon ODDS (%) | 2 days ago 49% | 2 days ago 55% |
Advertisement
MDT and
Correlation & Price change
A.I.dvisor indicates that over the last year, MDT has been loosely correlated with SYK. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if MDT jumps, then SYK could also see price increases.